Lurasidone HCl - A Long Term Phase 3 Study of Patients With Chronic Schizophrenia

• Status: Completed
• Trial end date: 2011-07-01
• Target enrollment: 0
• Participant gender: All

Summary

Lurasidone HCl is a compound being developed for the treatment of schizophrenia. This clinical study is designed to test the hypothesis that lurasidone is effective, tolerable, and safe as compared with quetiapine XR long term among schizophrenic outpatients with chronic schizophrenia.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sunovion
• Treatments: Lurasidone Hydrochloride; Quetiapine Fumarate

Criteria

Entry Criteria:

• Screening for the present study will take place after subjects' participation in Study D1050233 has been completed, and after providing informed consent.

Inclusion Criteria:

• Completed all required assessments on the final study visit in Study D1050233.

• Suitable for treatment in an outpatient setting.

Exclusion Criteria:

• Any chronic organic disease of the CNS (other than schizophrenia).

• Considered by the investigator to be at imminent risk of suicide or injury to self, others, or property.